Total Payments
$245,023
2024 Payments
$15,232
Companies
25
Transactions
320
Medicare Patients
845
Medicare Billing
$153,408
Payment Breakdown by Category
Other$128,892 (52.6%)
Consulting$53,679 (21.9%)
Travel$41,735 (17.0%)
Research$11,900 (4.9%)
Food & Beverage$8,793 (3.6%)
Education$25.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $111,748 | 40 | 45.6% |
| Consulting Fee | $53,679 | 16 | 21.9% |
| Travel and Lodging | $41,735 | 117 | 17.0% |
| Honoraria | $12,526 | 6 | 5.1% |
| Unspecified | $11,900 | 12 | 4.9% |
| Food and Beverage | $8,793 | 122 | 3.6% |
| Compensation for serving as faculty or as a speaker for a medical education program | $4,618 | 6 | 1.9% |
| Education | $25.00 | 1 | 0.0% |
Payments by Type
General
$233,123
308 transactions
Research
$11,900
12 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| JAZZ PHARMACEUTICALS INC. | $53,001 | 72 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $35,652 | 39 | $0 (2024) |
| Amgen Inc. | $35,550 | 51 | $0 (2019) |
| Celgene Corporation | $29,840 | 30 | $0 (2024) |
| Rigel Pharmaceuticals, Inc. | $29,614 | 26 | $0 (2024) |
| PFIZER INC. | $14,752 | 16 | $0 (2024) |
| Agios Pharmaceuticals, Inc. | $11,749 | 18 | $0 (2019) |
| SERVIER PHARMACEUTICALS LLC | $9,127 | 14 | $0 (2024) |
| Stemline Therapeutics Inc. | $9,125 | 17 | $0 (2024) |
| Kite Pharma, Inc. | $5,192 | 3 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $15,232 | 25 | Rigel Pharmaceuticals, Inc. ($12,395) |
| 2023 | $27,425 | 44 | Rigel Pharmaceuticals, Inc. ($17,219) |
| 2022 | $14,405 | 15 | SERVIER PHARMACEUTICALS LLC ($6,470) |
| 2021 | $14,193 | 16 | PFIZER INC. ($6,726) |
| 2020 | $9,952 | 14 | Stemline Therapeutics Inc. ($8,682) |
| 2019 | $39,834 | 54 | Amgen Inc. ($16,930) |
| 2018 | $43,480 | 67 | Jazz Pharmaceuticals Inc. ($26,221) |
| 2017 | $80,501 | 85 | Novartis Pharmaceuticals Corporation ($31,372) |
All Payment Transactions
320 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/07/2024 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $146.61 | General |
| Category: Oncology | ||||||
| 12/05/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $28.79 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,384.00 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 11/19/2024 | PFIZER INC. | ELREXFIO (Drug) | Food and Beverage | In-kind items and services | $25.79 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $14.56 | General |
| Category: Oncology | ||||||
| 11/07/2024 | Novartis Pharmaceuticals Corporation | — | — | Cash or cash equivalent | $1,204.72 | Research |
| Study: Research Publication/ Writing Support | ||||||
| 11/06/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $108.66 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 10/24/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,384.00 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 10/10/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $18.19 | General |
| Category: ONCOLOGY | ||||||
| 10/09/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $91.93 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 09/19/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Honoraria | Cash or cash equivalent | $1,713.00 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 08/28/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $16.70 | General |
| Category: ONCOLOGY | ||||||
| 06/29/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $18.94 | General |
| Category: ONCOLOGY | ||||||
| 06/21/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Food and Beverage | In-kind items and services | $14.68 | General |
| Category: Oncology | ||||||
| 06/20/2024 | Stemline Therapeutics Inc. | ELZONRIS (Drug) | Food and Beverage | In-kind items and services | $102.52 | General |
| Category: Oncology | ||||||
| 06/11/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $25.20 | General |
| Category: Oncology | ||||||
| 06/10/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $71.72 | General |
| Category: ONCOLOGY | ||||||
| 05/09/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $24.20 | General |
| Category: ONCOLOGY | ||||||
| 05/06/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $19.22 | General |
| Category: Hematology | ||||||
| 04/29/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Honoraria | Cash or cash equivalent | $1,713.00 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 03/27/2024 | Janssen Scientific Affairs, LLC | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $29.15 | General |
| Category: Oncology | ||||||
| 03/08/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $19.70 | General |
| Category: ONCOLOGY | ||||||
| 02/16/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,020.00 | General |
| Category: Oncology | ||||||
| 02/05/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $15.95 | General |
| Category: Hematology | ||||||
| 01/25/2024 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $21.08 | General |
| Category: Hematology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| AML CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $6,650 | 5 |
| A RANDOMIZED, OPEN-LABEL, CONTROLLED, PHASE 2 STUDY OF PEVONEDISTAT, VENETOCLAX, AND AZACITIDINE VERSUS VENETOCLAX PLUS AZACITIDINE IN ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA WHO ARE UNFIT FOR INTENSIVE CHEMOTHERAPY | Takeda Pharmaceuticals U.S.A., Inc. | $1,250 | 1 |
| PUBLICATION SUPPORT IN CONNECTION WITH HEOR RESEARCH | Novartis Pharmaceuticals Corporation | $1,245 | 1 |
| Research Publication/ Writing Support | Novartis Pharmaceuticals Corporation | $1,205 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | Novartis Pharmaceuticals Corporation | $825.00 | 2 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH RESEARCH AGREEMENT | Novartis Pharmaceuticals Corporation | $675.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 60 | 117 | $31,454 | $9,369 |
| 2022 | 4 | 196 | 355 | $93,493 | $32,364 |
| 2021 | 6 | 287 | 651 | $168,790 | $62,587 |
| 2020 | 8 | 302 | 593 | $148,665 | $49,088 |
Total Patients
845
Total Services
1,716
Medicare Billing
$153,408
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 12 | 47 | $10,468 | $2,920 | 27.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 11 | 29 | $7,825 | $2,643 | 33.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 16 | 19 | $7,136 | $2,128 | 29.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 21 | 22 | $6,025 | $1,678 | 27.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 64 | 128 | $38,539 | $14,040 | 36.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 25 | 92 | $20,023 | $7,011 | 35.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 54 | 69 | $15,321 | $4,914 | 32.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 20 | 30 | $8,962 | $3,300 | 36.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 13 | 13 | $5,598 | $1,754 | 31.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 20 | 23 | $5,051 | $1,346 | 26.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 85 | 211 | $61,739 | $23,775 | 38.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 47 | 248 | $53,070 | $19,782 | 37.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 56 | 70 | $15,190 | $5,087 | 33.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 24 | 41 | $11,997 | $4,560 | 38.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 21 | 24 | $10,010 | $3,757 | 37.5% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 20 | 20 | $8,612 | $2,765 | 32.1% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 19 | 19 | $4,268 | $1,526 | 35.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 15 | 18 | $3,906 | $1,335 | 34.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 42 | 198 | $42,370 | $16,541 | 39.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 53 | 113 | $33,064 | $9,996 | 30.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 64 | 111 | $24,087 | $6,495 | 27.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 37 | 57 | $16,678 | $5,033 | 30.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 24 | 26 | $10,844 | $4,229 | 39.0% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 15 | 15 | $6,459 | $1,981 | 30.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 25 | 28 | $6,076 | $1,726 | 28.4% |
About Dr. Tibor Kovacsovics, MD
Dr. Tibor Kovacsovics, MD is a Hematology & Oncology healthcare provider based in Portland, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1396750899.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Tibor Kovacsovics, MD has received a total of $245,023 in payments from pharmaceutical and medical device companies, with $15,232 received in 2024. These payments were reported across 320 transactions from 25 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($111,748).
As a Medicare-enrolled provider, Kovacsovics has provided services to 845 Medicare beneficiaries, totaling 1,716 services with total Medicare billing of $153,408. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Portland, OR
- Active Since 07/31/2006
- Last Updated 11/17/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1396750899
Products in Payments
- VYXEOS (Drug) $49,693
- RYDAPT (Drug) $30,899
- Kyprolis (Biological) $29,977
- Revlimid (Drug) $29,783
- Rezlidhia (Drug) $29,614
- TIBSOVO (Drug) $16,406
- ELZONRIS (Drug) $9,125
- Blincyto (Biological) $5,572
- DAURISMO (Drug) $5,433
- Tecartus (Drug) $5,000
- Gammaplex (Drug) $4,958
- Xospata (Drug) $3,606
- ONCASPAR (Drug) $3,110
- BESPONSA (Biological) $2,000
- Tibsovo (Drug) $1,020
- DARZALEX (Biological) $498.97
- Defitelio (Drug) $250.09
- DEFITELIO (Drug) $128.00
- Yescarta (Drug) $125.00
- TECVAYLI (Biological) $122.58
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Portland
Brian Druker, Md, MD
Hematology & Oncology — Payments: $1.5M
Hematology & Oncology $1.5M
Dr. Jay Andersen, M.d, M.D
Hematology & Oncology — Payments: $480,702
Hematology & Oncology $480,702
Rachel Sanborn, Md, MD
Hematology & Oncology — Payments: $322,427
Hematology & Oncology $322,427
Richard Maziarz, Md, MD
Hematology & Oncology — Payments: $246,109
Hematology & Oncology $246,109
John Godwin, Md, MD
Hematology & Oncology — Payments: $96,623
Hematology & Oncology $96,623
Dr. Rom Leidner, Md, MD
Hematology & Oncology — Payments: $79,796
Hematology & Oncology $79,796